Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Karyopharm Therapeutics Inc. (KPTI)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M | $108.1M | $40.9M | $30.3M | $1.6M | $154,000 | $250,000 | $229,000 | $387,000 | $634,000 | $152,000 | — | — |
| Research & development | $125.6M | $143.2M | $138.8M | $148.7M | $160.8M | $150.8M | $122.3M | $161.4M | $107.3M | $86.9M | $97.7M | $60.1M | $28.5M | $14.1M | $8.6M | — | — |
| Operating expenses | $236.8M | $264.7M | $275.6M | $299.3M | $308.1M | $279.9M | $230.2M | $210.2M | $132.1M | $110.9M | $119.3M | $76.1M | $34.3M | $16.5M | $10.5M | — | — |
| Operating income | −$90.7M | −$119.4M | −$129.5M | −$142.2M | −$98.3M | −$171.8M | −$189.3M | −$179.9M | −$130.5M | −$110.7M | −$119.1M | −$75.8M | −$34.0M | −$15.9M | −$10.3M | — | — |
| EBITDAderived | — | — | — | — | — | — | −$188.3M | −$179.1M | −$129.8M | −$110.0M | −$118.4M | −$75.5M | −$33.8M | −$15.8M | −$10.2M | — | — |
| Net income | −$196.0M | −$76.4M | −$143.1M | −$165.3M | −$124.1M | −$196.3M | −$199.6M | −$178.4M | −$129.0M | −$109.6M | −$118.2M | −$75.8M | −$33.9M | −$15.9M | — | — | — |
| Basic EPSper diluted share | -$17.93 | -$9.41 | -$18.79 | -$2.02 | -$1.65 | -$2.72 | -$3.22 | -$3.14 | -$2.81 | -$2.92 | -$3.32 | -$2.43 | -$5.59 | -$8.95 | -$10.27 | — | — |
| Diluted EPSper diluted share | -$17.93 | -$14.00 | -$18.79 | -$2.02 | -$1.65 | -$2.72 | -$3.22 | -$3.14 | -$2.81 | -$2.92 | -$3.32 | -$2.43 | -$5.59 | -$8.95 | -$10.27 | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 14, 2026Form 4 | Poulton StuartEVP, Chief Development Officer | SellCommon Stock | 403 | $9.50 | $3.8K | 94.8K |
| May 14, 2026Form 4 | Rangwala ReshmaEVP & Chief Medical Officer | SellCommon Stock | 408 | $9.50 | $3.9K | 56.8K |
| May 14, 2026Form 4 | Cheng Sohanya RoshanEVP & Chief Commercial Officer | SellCommon Stock | 324 | $9.50 | $3.1K | 107.9K |
| May 14, 2026Form 4 | Abate KristinChief Accounting Officer | SellCommon Stock | 53 | $9.50 | $503.50 | 23.8K |
| May 14, 2026Form 4 | Paulson Richard A.President and CEO | SellCommon Stock | 2.2K | $9.50 | $20.9K | 269.7K |